Ask Sterling

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Companies Sectors Ask Sterling Compare

Favorites

Revenue Breakdown

Chart: Revenue Breakdown for Akero Therapeutics. Values in USD billions. In Q3 2025: Revenue 0, Gross Profit 0, Operating Income -0.09.

Revenue Flow

Chart: Revenue Flow for Akero Therapeutics. Q3 2025, values in USD. Revenue 0, Cost of Revenue 0, Gross Profit 0, Net Income -0.082, Operating Income -0.09.

Balance Sheet

Chart: Balance Sheet for Akero Therapeutics. Values in currency. In Q3 2025: Total Assets 1.006, Total Liabilities 0.048, Total Equity 0.958.

Q4 2017-Q3 2025(All available data)

Cash Flow

Chart: Cash Flow for Akero Therapeutics. Values in currency. In Q3 2025: Operating Cash Flow -0.067, Free Cash Flow -0.067, Capital Expenditures 0.

Q4 2017-Q3 2025(All available data)

Akero Therapeutics (AKRO) - Compare | Sterling

Revenue Breakdown

Chart: Revenue Breakdown for Akero Therapeutics. Values in USD billions. In Q3 2025: Revenue 0, Gross Profit 0, Operating Income -0.09.

Revenue Flow

Chart: Revenue Flow for Akero Therapeutics. Q3 2025, values in USD. Revenue 0, Cost of Revenue 0, Gross Profit 0, Net Income -0.082, Operating Income -0.09.

Balance Sheet

Chart: Balance Sheet for Akero Therapeutics. Values in currency. In Q3 2025: Total Assets 1.006, Total Liabilities 0.048, Total Equity 0.958.

Q4 2017-Q3 2025(All available data)

Cash Flow

Chart: Cash Flow for Akero Therapeutics. Values in currency. In Q3 2025: Operating Cash Flow -0.067, Free Cash Flow -0.067, Capital Expenditures 0.

Q4 2017-Q3 2025(All available data)